CSIMarket



Sangui Biotech International Inc  (SGBI)
Other Ticker:  
 
 

SGBI's Revenue Growth by Quarter and Year

Sangui Biotech International Inc's Revenue results by quarter and year




SGBI Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter June - 0.01 0.01 0.02
III Quarter March 0.02 0.02 0.01 0.01
II Quarter December 0.02 0.01 0.01 0.04
I Quarter September 0.02 0.02 - 0.01
FY   0.06 0.06 0.03 0.08



SGBI Revenue third quarter 2022 Y/Y Growth Comment
Sangui Biotech International Inc reported fall in Revenue in the third quarter 2022 by -10.23% to $ 0.02 millions, from the same quarter in 2021.
The decline in the third quarter 2022 Sangui Biotech International Inc's Revenue compares unfavorably to the Company's average Revenue growth of 1.9%.

Looking into third quarter 2022 results within Biotechnology & Pharmaceuticals industry 94 other companies have achieved higher Revenue growth. While Sangui Biotech International Inc' s Revenue decrease of -10.23% ranks overall at the positon no. 3128 in the third quarter 2022.




SGBI Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter June - 0 % -50 % 100 %
III Quarter March -10.23 % 100 % 0 % 0 %
II Quarter December 100 % 0 % -75 % 0 %
I Quarter September 0 % - - -50 %
FY   - 100 % -62.5 % 0 %

Financial Statements
Sangui Biotech International Inc's third quarter 2022 Revenue $ 0.02 millions SGBI's Income Statement
Sangui Biotech International Inc's third quarter 2021 Revenue $ 0.02 millions Quarterly SGBI's Income Statement
New: More SGBI's historic Revenue Growth >>


SGBI Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter June - -50 % 0 % 100 %
III Quarter March -10.23 % 100 % 0 % -75 %
II Quarter December 0 % -50 % - 300 %
I Quarter September 100 % 100 % - 0 %
FY (Year on Year)   - 100 % -62.5 % 0 %




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #95
Healthcare Sector #487
Overall #3128

Revenue Y/Y Growth Statistics
High Average Low
67.78 % 1.9 % -48.85 %
(Sep 30 2020)   (Sep. 30, 2015)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #95
Healthcare Sector #487
Overall #3128
Revenue Y/Y Growth Statistics
High Average Low
67.78 % 1.9 % -48.85 %
(Sep 30 2020)   (Sep. 30, 2015)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Sangui Biotech International Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4042.91 % 159.73 % -98.85 %
(Dec 31 2019)  


SGBI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Sangui Biotech International Inc reported drop in Revenue from the second quarter by -10.23% to $ 0.02 millions, from $ 0.02 millions released in the previous quarter.

Albeit periodic factors normally elevate III. Quarter 2022 Revenue, it simply was not enough to rescue Biotechnology & Pharmaceuticals's company III. Quarter outcome, Diego Serrano, a business consultant pointed out and wrote that average quarter on quarter Revenue growth is at 159.73% for SGBI.

Within Biotechnology & Pharmaceuticals industry 85 other companies have achieved higher Revenue quarter on quarter growth. While Sangui Biotech International Inc's Revenue growth quarter on quarter, overall rank is 2930.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #86
Healthcare Sector #466
Overall #2930
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #86
Healthcare Sector #466
Overall #2930
Revenue Q/Q Growth Statistics
High Average Low
4042.91 % 159.73 % -98.85 %
(Dec 31 2019)  


SGBI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Sangui Biotech International Inc realized drop in Revenue sequentially by -10.23% to $ 0.02 millions, from $ 0.02 millions released in the previous reporting period.

Albeit seasonal factors normally elevate III. Quarter 2022 performance, this plainly was not enough to rescue Sangui Biotech International Inc's performance, Diego Serrano, a business consultant wrote.

Within Biotechnology & Pharmaceuticals industry 85 other companies have achieved higher Revenue quarter on quarter growth. While Sangui Biotech International Inc's Revenue growth quarter on quarter, overall rank is 2930.


Sangui Biotech International Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 0.07 $ 0.08 $ 0.06 $ 0.07 $ 0.06
Y / Y Revenue Growth (TTM) 21.89 % 59.39 % 32.47 % 126.82 % 30.05 %
Year on Year Revenue Growth Overall Ranking # 1375 # 59 # 665 # 233 # 597
Seqeuential Revenue Change (TTM) -4.26 % 17.86 % -2.01 % 10.24 % 25.19 %
Seq. Revenue Growth (TTM) Overall Ranking # 3128 # 49 # 3081 # 1184 # 229




Cumulative Revenue growth Comment
Assuming the Sangui Biotech International Inc's fiscal year would have ended in Mar 31 2022, Sangui Biotech International Inc would have reprted above average annual Revenue rise of 21.89% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 59.39% increase in Dec 31 2021.

In the Healthcare sector 218 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 59 to 1375.

Revenue TTM Q/Q Growth Statistics
High Average Low
67.78 %
1.9 %
-48.85 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 95
Healthcare Sector # 219
Overall # 1375

Revenue TTM Y/Y Growth Statistics
High Average Low
126.82 %
9.21 %
-67.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 95
Sector # 487
S&P 500 # 3128
Cumulative Revenue growth Comment
Assuming the Sangui Biotech International Inc's fiscal year would have ended in Mar 31 2022, Sangui Biotech International Inc would have reprted above average annual Revenue rise of 21.89% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 59.39% increase in Dec 31 2021.

In the Healthcare sector 218 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 59 to 1375.

Revenue TTM Q/Q Growth Statistics
High Average Low
67.78 %
1.9 %
-48.85 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 95
Healthcare Sector # 219
Overall # 1375

Revenue TTM Y/Y Growth Statistics
High Average Low
126.82 %
9.21 %
-67.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 95
Sector # 487
S&P 500 # 3128




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SGBI's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for SGBI's Competitors
Revenue Growth for Sangui Biotech International Inc's Suppliers
Revenue Growth for SGBI's Customers

You may also want to know
SGBI's Annual Growth Rates SGBI's Profitability Ratios SGBI's Asset Turnover Ratio SGBI's Dividend Growth
SGBI's Roe SGBI's Valuation Ratios SGBI's Financial Strength Ratios SGBI's Dividend Payout Ratio
SGBI's Roa SGBI's Inventory Turnover Ratio SGBI's Growth Rates SGBI's Dividend Comparisons



Companies with similar Revenue increase for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Hydrofarm Holdings Group Inc -0.01%$ -0.011 millions
Sage Therapeutics Inc.-0.06%$ -0.063 millions
Davita Inc.-0.09%$ -0.087 millions
Axogen inc.-0.10%$ -0.097 millions
Oncternal Therapeutics Inc -0.27%$ -0.267 millions
World Health Energy Holdings Inc.-0.33%$ -0.328 millions
Glaukos Corp-0.42%$ -0.422 millions
Collegium Pharmaceutical inc.-0.70%$ -0.699 millions
Tenet Healthcare Corp-0.75%$ -0.753 millions
Nevro Corp.-0.87%$ -0.867 millions
Antares Pharma Inc -1.25%$ -1.250 millions
Elanco Animal Health Inc-1.37%$ -1.369 millions
Nanostring Technologies Inc.-1.70%$ -1.698 millions
Mimedx Group Inc.-1.79%$ -1.789 millions
Exagen Inc.-1.82%$ -1.823 millions
Royalty Pharma Plc-1.92%$ -1.916 millions
Veru Inc -2.34%$ -2.339 millions
Delcath Systems Inc.-2.58%$ -2.577 millions
Ikena Oncology Inc -2.59%$ -2.591 millions
Therapeuticsmd Inc -2.68%$ -2.683 millions
Ngm Biopharmaceuticals Inc.-2.91%$ -2.906 millions
Livanova Plc-3.00%$ -3.000 millions
Lifevantage Corp-3.04%$ -3.037 millions
Reata Pharmaceuticals Inc.-3.18%$ -3.178 millions
Bio rad Laboratories Inc.-3.68%$ -3.678 millions
Codiak Biosciences Inc.-3.69%$ -3.692 millions
Vanda Pharmaceuticals Inc.-3.95%$ -3.953 millions
Quest Diagnostics Inc-4.01%$ -4.007 millions
Organogenesis Holdings Inc -4.32%$ -4.325 millions
Myriad Genetics Inc.-4.74%$ -4.737 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CHRD's Profile

Stock Price

CHRD's Financials

Business Description

Fundamentals

Charts & Quotes

CHRD's News

Suppliers

CHRD's Competitors

Customers & Markets

Economic Indicators

CHRD's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071